Physician profile
Timothy Thompson
NPI 1578747390
$985.50
in general payments reported to CMS, 2019-2025
14 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $61.86 · 2021: $70.64 · 2022: $163 · 2023: $104 · 2024: $131 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $569.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $306.06 | 2021-2025 | Dupixent, Libtayo |
| Stryker Corporation | $275.50 | 2019-2025 | Scopis Ent, Xpress Loprofile, Xpress Ent Dilation System |
| Olympus America INC. | $56.00 | 2019-2022 | |
| Glaxosmithkline, LLC. | $55.15 | 2025 | Nucala |
| Inspire Medical Systems, INC. | $49.10 | 2023-2025 | Inspire |
| Aerin Medical INC. | $48.61 | 2025 | |
| Kaleo, INC. | $43.63 | 2022 | |
| Optinose US, INC. | $43.53 | 2022-2023 | |
| Amgen INC. | $24.97 | 2025 | Tezspire |
| Merck Sharp & Dohme LLC | $23.49 | 2023 | Verquvo |
| Intersect Ent, INC. | $20.09 | 2020 | |
| Genzyme Corporation | $14.67 | 2021 | |
| Hikma Pharmaceuticals USA | $13.59 | 2023 | Ryaltris |
| Arbor Pharmaceuticals, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.